Chemotherapy for diffuse large-cell lymphoma - Rapidly responding patients have more durable remissions

J. O. Armitage, D. D. Weisenburger, M. Hutchins, D. F. Moravec, M. Dowling, S. Sorensen, J. Mailliard, J. Okerbloom, P. S. Johnson, D. Howe

Research output: Contribution to journalArticlepeer-review

144 Scopus citations


Fifty-one patients with diffuse large-cell lymphoma (DLCL) were treated with a six-drug combination chemotherapy regimen including cyclophosphamide, doxorubicin, procarbazine, bleomycin, vincristine, and prednisone. The patients were restaged after three cycles of therapy, and restaging was repeated at 2-month intervals in patients who had persistent disease. Responding patients received two cycles of therapy after documentation of complete remission (CR). With all patients considered evaluable, 73% of the patients achieved a CR. Twenty-six of the 37 CRs (70%) achieved remission in the first three treatment cycles. The durability of remission in the rapidly responding patients was significantly better than for patients who required five cycles to achieve CR (80% v 40% at 2 years, P = .02) despite the latter patients having received two more cycles of therapy. Rapidly responding patients with DLCL do not require prolonged therapy and have a better prognosis than patients achieving a CR more slowly.

Original languageEnglish (US)
Pages (from-to)160-164
Number of pages5
JournalJournal of Clinical Oncology
Issue number2
StatePublished - 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Chemotherapy for diffuse large-cell lymphoma - Rapidly responding patients have more durable remissions'. Together they form a unique fingerprint.

Cite this